RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Pharmacoepidemiology and "in silico" drug evaluation: Is there common ground?
Stuermer, T., Rothman, K., & Avorn, J. (2008). Pharmacoepidemiology and "in silico" drug evaluation: Is there common ground?Journal of Clinical Epidemiology, 61(3), 205-206. https://doi.org/10.1016/j.jclinepi.2007.07.006
Shortcomings of randomized trials have long been recognized by medical researchers [ 1 , 2 ]. These shortcomings include a reduced range of risk factors for the outcome among patients enrolled in preapproval trials. The reduced range enhances the validity of the trials, but the patient populations are highly selected compared with the broad range of risk factors represented among patients who are eventually treated with the drug. This restriction may reduce the generalizability of the findings from those studied to those with different baseline risks.
